Status:

COMPLETED

Investigation of Efficacy and Safety of Electrical Signal Therapy Provided by Dr Biolyse® Device in COVID-19 Disease

Lead Sponsor:

AVB Biotechnology

Conditions:

COVID-19 Pneumonia

Virus Diseases

Eligibility:

All Genders

18-65 years

Phase:

NA

Brief Summary

Dr. Biolyse® is a device with artificial intelligence that works in sync with the immune system and can be integrated like an element of this system. It is designed to develop chemical immunity within...

Eligibility Criteria

Inclusion

  • Men and women between the ages of 18-65
  • Patients with mild moderate complicated or uncomplicated COVID 19 pneumonias
  • Those who accept to be followed up and treated as an inpatient
  • Those who have at least one laboratory and clinical finding that can be evaluated during follow-up

Exclusion

  • Patients with severe course or COVID 19 pneumonia requiring intensive care follow-up
  • Pregnant or breastfeeding women
  • Epilepsy, Arrhythmia, Dementia, heart failure, severe lung disease, patients with active malignancy and those with pacemaker
  • "Vulnerable Population" patients defined in ICU

Key Trial Info

Start Date :

September 1 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 15 2024

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT06113757

Start Date

September 1 2022

End Date

April 15 2024

Last Update

July 5 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Bezmialem Vakif University Dragos Hospital

Istanbul, Turkey (Türkiye)

Investigation of Efficacy and Safety of Electrical Signal Therapy Provided by Dr Biolyse® Device in COVID-19 Disease | DecenTrialz